-
BMJ: Changes in PM2.5 exposure levels in the residential environment are closely related to the risk of death from cardiovascular and respiratory diseases
Time of Update: 2021-11-02
5 exposure due to changes in the living environment will affect the risk of death of residents.
5 exposure due to changes in the living environment will affect the risk of death of residents.
-
Detailed Nature Paper: Discovery of a new leucine receptor protein SAR1B that regulates lung cancer through mTORC1
Time of Update: 2021-11-02
2021 Nian 7 Yue 21 days, the future Institute of Technology School of Molecular Medicine, Peking University, Beijing University - Tsinghua University Joint Center for Life Sciences, Beijing future genetic diagnosis -tech innovation center Liu Ying Task Force in Nature published online entitled: Sar1b Senses Leucine Levels to regulate mTORC1 signalling 's research paper .
-
Science Sub-Journal: Xiamen University's Liu Wenxian team reveals a new mechanism that regulates the migration of mature T cells from the thymus to the periphery
Time of Update: 2021-11-02
This study reveals the important functions and regulatory mechanisms of the GSK3/β-catenin signaling pathway in regulating the migration of thymic mature T cells from the thymus, and provides a new molecular mechanism analysis for the signal regulation of T cell development and migration .
-
J Thorac Oncol: Long-term efficacy of nivolumab + ipilimumab in the treatment of advanced non-small cell lung cancer
Time of Update: 2021-11-02
Compared with chemotherapy, nivolumab combined with ipilimumab can prolong the overall survival of NSCLC patients with non-small cell lung cancer ( NSCLC ) whose tumor programmed death ligand 1 (PD-L1) expression is ≥1%This article reports the results of the CheckMate 227 study, which was followed up for the shortest 4 years .
-
JAMA Oncol: For hormone receptor-positive breast cancer, Pabocinil ➕Letrozole is better than Pabocinib ➕Fulvestrant
Time of Update: 2021-11-02
Although fulvestrant-palbociclib showed significant anti-tumor activity, this randomized clinical trial failed to determine that the regimen is comparable to letrozole-palbociclib in patients with endocrine-sensitive, hormone receptor-positive, and ERBB2- negative advanced breast cancer.
-
Lancet Oncol: CDKI combined with Fulvestrant is expected to become the standard treatment for hormone receptor-positive and HER2-negative advanced breast cancer!
Time of Update: 2021-11-02
Cyclin-dependent kinase 4/6 inhibitor (CDKI) is an oral targeted drug that has been approved in combination with endocrine therapy as the first-line or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer .
-
10 typical cases, let you learn how to diagnose bone tumors
Time of Update: 2021-11-02
Chondromycinoma Requirements for imaging diagnosisRequirements for imaging diagnosis To determine whether the bone lesion is a tumor, benign or malignant, whether it is primary or metastatic, and infer the tumor grade type, the key is to determine the benign and malignant tumor .
-
Lancet Oncol: Liposome irinotecan combined with leucovorin and fluorouracil may become the second-line standard treatment for advanced biliary tract cancer!
Time of Update: 2021-11-02
8 months, and progression-free survival median BICR assessment of the experimental group was significantly longer than the control group (7.
8 months, and progression-free survival median BICR assessment of the experimental group was significantly longer than the control group (7.
-
Circulation: Which is the relative cardiovascular safety of GnRH antagonists and agonists?
Time of Update: 2021-11-02
This is an international, multi-center, prospective, randomized, open-label clinical trial, recruiting prostate cancer patients with atherosclerotic cardiovascular disease, randomly (1:1) divided into two groups, receiving GnRH antagonism Intervention treatment with degarelix or GnRH agonist leuprolide for 12 months .
-
Avasopasem for treatment of severe oral mucositis induced by radiotherapy, the phase III ROMAN trial failed to reach the primary endpoint
Time of Update: 2021-11-02
preventionGalera Therapeutics, a clinical-stage biopharmaceutical company, today announced the results of the avasopasem phase III ROMAN trial, which evaluated avasopasem treatment of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) who received standard radiotherapy.
-
10-year data on Chinese women: Which early breast cancer patients undergoing breast-conserving surgery are more likely to relapse locally?
Time of Update: 2021-11-02
Some clinicopathological risk factors, including younger onset, lobular histology, high grade, late manifestation, and specific molecular subtypes , have been shown to predict the increase in local recurrence rates after BCS and whole breast radiotherapy .
-
Eur J Cancer: Efficacy of Cabozantinib in the Treatment of Metastatic Renal Cell Carcinoma: An Analysis of CABOREAL Results from Real-World Research
Time of Update: 2021-11-02
This largest real-world data shows that Cabozantinib is effective for patients with metastatic renal cell carcinoma who have not selected previous treatments .
This largest real-world data shows that Cabozantinib is effective for patients with metastatic renal cell carcinoma who have not selected previous treatments .
-
JAAD: How to distinguish irritant seborrheic keratosis from squamous cell carcinoma
Time of Update: 2021-11-02
The main dermoscopic predictors of SCC are punctate blood vessels (odds ratio [OR], 10.
Heymann, Irritated seborrheic keratosis versus squamous cell carcinoma: Circling in on their differentiation, Journal of the American Academy of Dermatology,Volume 85, Issue 5,2021,Pages 1119-1120, ISSN 0190-9622, https: //doi.
-
JCO: For advanced biliary tract cancer, is triple chemotherapy better than double chemotherapy?
Time of Update: 2021-11-02
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study .
00679Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study in this message
-
Front Oncol: Pyrotinib-based treatment of HER2+ advanced breast cancer patients: a multi-center retrospective study
Time of Update: 2021-11-02
In an open-label phase II study, pigtinib + capecitabine had significantly longer progression-free survival (PFS) in her2-positive breast cancer patients compared with lapatinib + capecitabine (18.
In an open-label phase II study, pigtinib + capecitabine had significantly longer progression-free survival (PFS) in her2-positive breast cancer patients compared with lapatinib + capecitabine (18.
-
Front Oncol: Efficacy of pyrrotinib combined with vinorelbine in the treatment of HER2-positive metastatic breast cancer: a multicenter retrospective study
Time of Update: 2021-11-02
In addition, 67% of patients received 2-line or more systemic treatment before pyrrotinib combined with vinorelbine .
In addition, 67% of patients received 2-line or more systemic treatment before pyrrotinib combined with vinorelbine .
-
Cancer Cell: Zhang Zemin's team and others reveal the mechanism of action of anti-PD-L1 immunotherapy combined with chemotherapy in triple-negative breast cancer
Time of Update: 2021-11-02
On October 14, 2021, Peking University's Biomedical Frontier Innovation Center (BIOPIC) Zhang Zemin's research team, together with Liu Zhihua's research team, Ma Fei's and Xu Binghe's research team from the Cancer Hospital of the Chinese Academy of Medical Sciences, published an online publication on Cancer Cell, the top journal of oncology The research paper titled: Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple negative breast cancer .
-
Lancet Oncol: Nivolumab may become a new choice for malignant mesothelioma that has progressed after first-line treatment!
Time of Update: 2021-11-02
The median progression-free survival in the nivolumab group and placebo group were 3.
The median progression-free survival of nivolumab and placebo groups were 3.
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
-
Int J Epidemiol: Common genetic polymorphisms increase the link between chronic lymphocytic leukemia and non-melanoma skin cancer
Time of Update: 2021-11-02
Cancer (BCC), 825 cases of squamous cell carcinoma (SCC) and 12802 cases of controlled studies studied the relationship between the identified CLL locus and the risk of NMSC .
-
J Urol: Among high-risk and very high-risk prostate cancer patients, which of radical prostatectomy or radiation therapy has a higher survival rate?
Time of Update: 2021-11-02
They reported on high-risk (HR) patients of the National Comprehensive Cancer Network (NCCN) and Johns Hopkins University (JH) high-risk (HR) and very high-risk (VHR) In the subgroup, the cancer-specific mortality (CSM) of radical prostatectomy (RP) and external radiotherapy (EBRT) were compared .
